Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gap closed, looking for the hammer! $ELTP
Is exactly what "they" have been working for by dominating the conversation with Fear Uncertainty and Doubt. Do you really think that if there was some malfeasance, the cockroaches of this world wouldn't have taken action already? The particular Mikah situation has been known for years, is stated in Q's and K's and NOW they want to discuss it and bring it to light? Or....is it because they know $ELTP is poised to finally be valuated at what it's worth and they are willing to do anything to try and get more shares. Notice how some will be pro $ELTP, particularly when there is a good chance for a ramp up of the stock price (before expected news or financial reports) and once the news/event comes, they shift to negative mode. Here's where they start to bash and call into question every move that could possibly create FUD. It's an old game, but effective. Creating fear and doubt discourages new buyers, they sell shares to bring the price down, then rebuy when the stock has been beaten lower. Then they turn positive again and the cycle continues.
We're looking at a year of possibly $50 million plus in revenues. No need to say any more than that.
“Just to give you a little history, in 2019, our revenues were $7.6 million for full year, full 12 months. In 2020 -- fiscal year 2020, it was $18 million. And then 2021, it was $25 million. 2022, it was $32 million and last fiscal year ended March 31st, 2023, it was $34 million.”
-Carter Ward-
“Last year's revenues were $34 million. Within nine months, ………… we've achieved $39 million, and we still have a quarter to go.”
-Nasrat Hakim-
“Just to give you a little history, in 2019, our revenues were $7.6 million for full year, full 12 months. In 2020 -- fiscal year 2020, it was $18 million. And then 2021, it was $25 million. 2022, it was $32 million and last fiscal year ended March 31st, 2023, it was $34 million.”
-Carter Ward-
“Last year's revenues were $34 million. Within nine months, ………… we've achieved $39 million, and we still have a quarter to go.”
-Nasrat Hakim-
Global M&A Trends in Health Industries
From Pricewaterhouse Coopers 2024 Outlook
"Pharmaceuticals and life sciences (PLS) and healthcare services (HCS) M&A remained resilient in 2023, with innovative companies that can drive value attracting substantial investor interest. We expect dealmaking to accelerate off this baseline in 2024, as has already been observed with a pickup in M&A activity toward the end of 2023 and in the first few weeks of 2024."
"Biotech acquisitions to fend off patent cliffs: Large-cap pharma companies will continue to face patent cliffs and gaps in their pipelines in the latter half of this decade and will look for M&A opportunities to achieve their growth plans. Small and midsize biotech companies that can fill in pipeline gaps in the back half of the decade will receive significant attention in 2024."
https://www.pwc.com/gx/en/services/deals/trends/health-industries.html
$5.1 Billion!!!
ELTP on 12/21/2023 “…announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product.”
- PR 12/26/23 -
“Regarding the research and development pipeline, Elite has four ANDAs, filed under FDA reviews.”
-Nasrat Hakim-
“Last year's revenues were $34 million. Within nine months, ………… we've achieved $39 million, and we still have a quarter to go.”
-Nasrat Hakim-
“Just to give you a little history, in 2019, our revenues were $7.6 million for full year, full 12 months. In 2020 -- fiscal year 2020, it was $18 million. And then 2021, it was $25 million. 2022, it was $32 million and last fiscal year ended March 31st, 2023, it was $34 million.”
-Carter Ward-
“Regarding the research and development pipeline, Elite has four ANDAs, filed under FDA reviews.”
-Nasrat Hakim-
“Last year's revenues were $34 million. Within nine months, ………… we've achieved $39 million, and we still have a quarter to go.”
-Nasrat Hakim-
“Revenues are up 67%. Operating profits are up 77%. Nine months revenue are already more than last year's 12 months revenue.
Our working capital is increasing, our debt is low, and our balance sheet is strong and continues to strengthen.’
-Carter Ward-
.123 window needs to close
$ELTP
Small gap from Oct 20th closed, would have been a great position to sit on and wait for the window to shut. It's a clear runway now and ready for an extended run, imo. Let's hear some news! $ELTP
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173096144
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173096455
Tick tock....CNS Stimulant ANDA soon!
"today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product."
"Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration."
https://finance.yahoo.com/news/elite-pharmaceuticals-reports-positive-results-100000340.html
$AMMX Golden Cross set up coming...maybe next week?
They've had the 40 dram for awhile, does this mean they didn't offer it to Canada? Or is this just a pump to sell shares?
October 01, 2018 08:30 ET | Source: Acology Inc.
CORONA, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- MedTainer Inc. (ACOL-OTC) announced today that Aurora Cannabis (OTCMARKETS:ACBFF,TSE:ACB) has placed its’ 7th order for thousands of MedTainers in anticipation of the mid-October start to Canada’s legal recreational cannabis market. The company states that it anticipated and is well-prepared to fulfill the increased influx of orders for their signature multi-functional, certified child-resistant, FDA-approved container.
The company also introduced a new size 40-dram MedTainer to the market, doubling the size of its’ signature product. This is in keeping with the anticipated demand of consumers who will want larger quantities of retail flower cannabis and make it easier to classify and label retail cannabis, as demanded by Canadian federal law.
MedTainer Inc. feels that these events signal a continuation of its steady Canadian expansion, predicted last year and continuing this year once the Canadian Legislature approved cannabis for legal recreational use. MedTainer Inc. continues to see a steady expansion in North America and anticipates that with the offer of multiple-sized, multiple-function containers this trend will continue. MedTainer Inc. anticipates doubling its’ sales and profits in 2019.
290.5 million shares added to float since January.
$ACOL
Of course this investor has, here's the portion of the reply I received today that pertains.
"We have always invested money back into the company, and that hasn't changed. Our executives, Doug and Curt, have relatively small salaries compared to similar executives in like companies. Much of the money that they have made is shoveled back into the company, which is in keeping with our mission statement that we would grow the company from the inside-out."
$ACOL
Post looks great in the stickies Nas, nice work!
$AMMX
Stilling...as in making moon shine?!? That would be awesome! No, I don't think they're stealing shareholder money, they're a public company, and public companies sell shares to get cash. I would like to know more than "most monies are invested back in the company" line I continue to get. A r/s....is possible, but not likely unless they do it from a position of strength (locked down a major contract with a LP or something significant), would hurt Doug and Curt more than any investor here.
$ACOL
Do you think ticker changes are free? No, they're not, but certainly not $442,000 dollars. This investor would prefer a little more communication from the company stating why they increased the float by near 90,000,000 shares since June, and what they're using the $822,000 raised, for.
$ACOL
$442,000 for a name change? What aren't we being told?
$ACOL
I agree 100%....$ACOL
LOL....$ACOL
Really?
"Business is up 33% over same period last year and trending higher
Sales exceeded $1.1 M, which reflected a nearly 10% increase over the past year"